NCT04544319View on ClinicalTrials.gov

Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

PHASE1UnknownINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

July 31, 2021

Conditions
T2DM
Interventions
DRUG

Zemiglo 50mg and Forxiga 10mg

Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD

DRUG

Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg

Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT04544319 - Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg | Biotech Hunter | Biotech Hunter